Holthof LC, van der Horst HJ, Veen SE van H- van, Ruiter RW, Li F, Buijze M, Andersen MN, Yuan H, de Bruijn J, van de Donk NW, Lokhorst HM, Zweegman S, Groen RW, Mutis T. Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma. Haematologica 2020; 105(2):e80-e83; https://doi.org/10.3324/haematol.2018.213314.